Literature DB >> 20813872

Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease.

A Ginestroni1, M Battaglini, S Diciotti, R Della Nave, L N Mazzoni, C Tessa, M Giannelli, S Piacentini, N De Stefano, M Mascalchi.   

Abstract

BACKGROUND AND
PURPOSE: GM is typically affected in HD since the presymptomatic stage. Our aim was to investigate with MT MR imaging the microstructural changes of the residual brain subcortical and cortical GM in carriers of the HD gene and to preliminarily assess their correlation with the clinical features.
MATERIALS AND METHODS: Fifteen HD gene carriers with a range of clinical severity and 15 age- and sex-matched healthy controls underwent MT MR imaging on a 1.5T scanner. The MT ratio was measured automatically in several subcortical and cortical GM regions (striatal nuclei; thalami; and the neocortex of the frontal, temporal, parietal, and occipital lobes) by using FLS tools.
RESULTS: The MT ratio was significantly (P < .05 with Bonferroni correction for multiple comparison) decreased in all subcortical structures except the putamen and decreased diffusely in the cerebral cortex of HD carriers compared with controls. Close correlation was observed between the subcortical and cortical regional MT ratios and several clinical variables, including disease duration, motor disability, and scores in timed neuropsychological tests.
CONCLUSIONS: MT imaging demonstrates degeneration of the subcortical and cortical GM in HD carriers and might serve, along with volumetric assessment, as a surrogate marker in future clinical trials of HD.

Entities:  

Mesh:

Year:  2010        PMID: 20813872      PMCID: PMC7964012          DOI: 10.3174/ajnr.A2225

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  31 in total

1.  Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.

Authors:  D C Rubinsztein; J Leggo; R Coles; E Almqvist; V Biancalana; J J Cassiman; K Chotai; M Connarty; D Crauford; A Curtis; D Curtis; M J Davidson; A M Differ; C Dode; A Dodge; M Frontali; N G Ranen; O C Stine; M Sherr; M H Abbott; M L Franz; C A Graham; P S Harper; J C Hedreen; M R Hayden
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and in progressive supranuclear palsy.

Authors:  H Hanyu; T Asano; H Sakurai; M Takasaki; H Shindo; K Abe
Journal:  Neuroradiology       Date:  2001-07       Impact factor: 2.804

3.  Variation of selective gray and white matter atrophy in Huntington's disease.

Authors:  Robert Jech; Jirí Klempír; Josef Vymazal; Jana Zidovská; Olga Klempírová; Evzen Růzicka; Jan Roth
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

4.  Nonisotopic method for accurate detection of (CAG)n repeats causing Huntington disease.

Authors:  M Muglia; O Leone; G Annesi; A L Gabriele; E Imbrogno; C Grandinetti; F L Conforti; F Naso; C Brancati
Journal:  Clin Chem       Date:  1996-10       Impact factor: 8.327

5.  Regional specificity of brain atrophy in Huntington's disease.

Authors:  G M Halliday; D A McRitchie; V Macdonald; K L Double; R J Trent; E McCusker
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

Review 6.  Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease.

Authors:  India Bohanna; Nellie Georgiou-Karistianis; Anthony J Hannan; Gary F Egan
Journal:  Brain Res Rev       Date:  2008-04-09

7.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

Review 8.  Huntington disease models and human neuropathology: similarities and differences.

Authors:  Jean Paul G Vonsattel
Journal:  Acta Neuropathol       Date:  2007-11-03       Impact factor: 17.088

9.  Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain.

Authors:  Mario Mascalchi; Francesco Lolli; Riccardo Della Nave; Carlo Tessa; Raffaele Petralli; Cinzia Gavazzi; Letterio S Politi; Marco Macucci; Massimo Filippi; Silvia Piacentini
Journal:  Radiology       Date:  2004-06-23       Impact factor: 11.105

10.  Magnetization transfer imaging in 'premanifest' Huntington's disease.

Authors:  Caroline K Jurgens; Reineke Bos; Jasper Luyendijk; Marie-Noëlle W Witjes-Ané; Jeroen van der Grond; Huub A M Middelkoop; Raymund A C Roos
Journal:  J Neurol       Date:  2009-10-13       Impact factor: 4.849

View more
  10 in total

1.  Magnetization transfer imaging demonstrates a distributed pattern of microstructural changes of the cerebral cortex in amyotrophic lateral sclerosis.

Authors:  M Cosottini; I Pesaresi; S Piazza; S Diciotti; G Belmonte; M Battaglini; A Ginestroni; G Siciliano; N De Stefano; M Mascalchi
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

2.  Magnetization transfer imaging in premanifest and manifest Huntington disease.

Authors:  S J A van den Bogaard; E M Dumas; J Milles; R Reilmann; J C Stout; D Craufurd; M A van Buchem; J van der Grond; R A C Roos
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-12       Impact factor: 3.825

Review 3.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

4.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

5.  Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up.

Authors:  S J A van den Bogaard; E M Dumas; E P Hart; J Milles; R Reilmann; J C Stout; D Craufurd; C R Gibbard; S J Tabrizi; M A van Buchem; J van der Grond; R A C Roos
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-23       Impact factor: 3.825

Review 6.  Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.

Authors:  Elizabeth H Aylward
Journal:  Mov Disord       Date:  2014-08-27       Impact factor: 10.338

7.  Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis.

Authors:  Nicola De Stefano; Maria Laura Stromillo; Francesca Rossi; Marco Battaglini; Antonio Giorgio; Emilio Portaccio; Bahia Hakiki; Gianmichele Malentacchi; Claudio Gasperini; Mario Santangelo; Maria Letizia Bartolozzi; Maria Pia Sormani; Antonio Federico; Maria Pia Amato
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Linking white matter and deep gray matter alterations in premanifest Huntington disease.

Authors:  Andreia V Faria; J Tilak Ratnanather; Daniel J Tward; David Soobin Lee; Frieda van den Noort; Dan Wu; Timothy Brown; Hans Johnson; Jane S Paulsen; Christopher A Ross; Laurent Younes; Michael I Miller
Journal:  Neuroimage Clin       Date:  2016-02-26       Impact factor: 4.881

9.  Mapping cortical degeneration in ALS with magnetization transfer ratio and voxel-based morphometry.

Authors:  Mirco Cosottini; Paolo Cecchi; Selina Piazza; Ilaria Pesaresi; Serena Fabbri; Stefano Diciotti; Mario Mascalchi; Gabriele Siciliano; Ubaldo Bonuccelli
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

10.  Examination of Huntington's disease in a Chinese family.

Authors:  Mingxia Yu; Xiaogai Li; Sanyun Wu; Ji Shen; Jiancheng Tu
Journal:  Neural Regen Res       Date:  2014-02-15       Impact factor: 5.135

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.